3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
10
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Interventions
Nivolumab
3
selinexor
2
pembrolizumab
2
pazopanib
2
Radiotherapy
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Ifosfamide
2
Doxorubicin
2
tazemetostat
1
metarrestin
1
fludarabine phosphate
1
fludarabine
1
Specimen Handling
1
Sirolimus
1
Proton Therapy
1
Mesna
1
Ipilimumab
1
Cyclophosphamide
1
CTLA-4 Antigen
1
BO-112
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neurofibrosarcoma
×
Ado-Trastuzumab Emtansine
×
90 days
×
Clear all
No trials found.